FDA Rejection, Evox-Rett Partnership, AI in Healthcare, Rezatapopt Study, Alzheimer's LLM Framework

In today's episode, we delve into the unexpected FDA rejection of a rare disease drug initially deemed approvable, highlighting the complexities of the drug approval process. We also explore Evox Therapeutics' partnership with the Rett Syndrome Research Trust to develop gene editing therapies using their ExoEdit® platform. NEJM AI emphasizes the need for rigorous trials and ethical considerations in healthcare AI development. The ViVE 2026 conference shifts focus from AI scribes to strategic applications, amid regulatory discussions on AI's role in insurance. Researchers initiate a Phase 1 study of Rezatapopt for TP53 Y220C mutation-related cancers, showing promising early results. Finally, a novel framework using large language models enhances Alzheimer's drug prioritization, offering a scalable approach to accelerate drug repurposing. https://www.lucidhealthsolutions.com https://www.lucidhealthsolutions.com 📚 Sources: https://www.statnews.com/2026/02/25/sarepta-ceo-doug-ingram-to-retire/ https://www.biospace.com/press-releases/evox-therapeutics-partners-with-rett-syndrome-research-trust-to-evaluate-exoedit-technology-to-enable-gene-editing-in-rett-syndrome https://ai.nejm.org/ https://www.modernhealthcare.com/health-tech/mh-vive-2026-ai-agents-ambient-scribes/ https://www.nejm.org/doi/full/10.1056/NEJMoa2508820 https://www.nature.com/articles/s44401-026-00074-3